Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Study of Dasatinib in Combination With Zoledronic Acid for the Treatment of Breast Cancer With Bone Metastasis

NCT00566618 is registered in ClinicalTrials.gov with M.D. Anderson Cancer Center as lead sponsor.

NCT NCT00566618
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00566618 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Study of Dasatinib in Combination With Zoledronic Acid for the Treatment of Breast Cancer With Bone Metastasis
Lead sponsor
M.D. Anderson Cancer Center
Phase
Phase 1/2
Overall status
Completed
Start date
November 1, 2007
Completion date
November 17, 2020
Enrollment
31 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

bone metastases, breast cancer